Search Results

You are looking at 1 - 10 of 33 items for :

  • "Graves’ disease" x
Clear All
Open access

Jan Calissendorff and Henrik Falhammar

Introduction Gravesdisease (GD) is common and can be treated by medication blocking thyroid hormone synthesis with drugs such as methimazole, carbimazole or propylthiouracil. With medication for 12–18 months, cure can be achieved, which is

Open access

Xuechao Jiang, Yonghui Wang, Xiaoying Li, Leqi He, Qian Yang, Wei Wang, Jun Liu and Bingbing Zha

Introduction Gravesdisease (GD) is the most common cause of hyperthyroidism and diffuse goiter, affecting 1.0–1.5% of the population ( 1 ). GD is characterized by lymphocytic infiltration and the production of autoantibodies directed against

Open access

Mengxue Yang, Bowen Sun, Jianhui Li, Bo Yang, Jie Xu, Xue Zhou, Jie Yu, Xuan Zhang, Qun Zhang, Shan Zhou and Xiaohua Sun

Introduction Gravesdisease (GD) is an organ-specific autoimmune thyroid disease (AITD) ( 1 , 2 ) and the most common cause of hyperthyroidism in iodine-sufficient geographical areas ( 3 ). According to the literature, the prevalence of

Open access

Suvanjaa Sivalingam, Marianne Thvilum, Thomas Heiberg Brix, Laszlo Hegedüs and Frans Brandt

Introduction Hyperthyroidism is a common condition with a lifetime risk of 2–10% ( 1 , 2 ). Gravesdisease (GD) and toxic nodular goitre (TNG) are the most frequent causes of hyperthyroidism ( 2 ). GD is an organ specific autoimmune disease

Open access

Aleksandra Krygier, Ewelina Szczepanek-Parulska, Dorota Filipowicz and Marek Ruchała

microcytosis (decreased MCV with normal haemoglobin) was detected in 57.4% of patients ( 4 ). The most common cause of hyperthyroidism is autoimmune Gravesdisease (GD). Immunologic factors, acting via inflammatory markers, might be an additional underlying

Open access

Adriano N Cury, Verônica T Meira, Osmar Monte, Marília Marone, Nilza M Scalissi, Cristiane Kochi, Luís E P Calliari and Carlos A Longui

Introduction Graves' disease (GD) accounts for 10–15% of all childhood thyroid abnormalities and is rare in those under age 5 years – its incidence peaks between age 11 and 15 years, predominantly affecting females (1, 2) . There is

Open access

Muthiah Subramanian, Manu Kurian Baby and Krishna G Seshadri

Introduction Although antithyroid drugs (ATDs) and partial thyroidectomy have established the treatment modalities, radioiodine therapy has become the primary treatment option of hyperthyroidism in Graves' disease (1, 2) . A number of interrelated

Open access

Lauren Bell, Ann Louise Hunter, Angelos Kyriacou, Annice Mukherjee and Akheel A Syed

Introduction Thyrotoxicosis, a clinical state resulting from inappropriately high thyroid hormone levels, is a condition with multiple aetiologies ( 1 ). It is commonly caused by Gravesdisease (GD), toxic multinodular goitre (TMNG) or toxic

Open access

Weiwei He, Bin Wang, Kaida Mu, Jing Zhang, Yanping Yang, Wei Yao, Sheli Li and Jin-an Zhang

AITDs and disease progression ( 7 , 8 ). AITDs mainly have two types of symptoms, Gravesdisease (GD) and Hashimoto’s thyroiditis (HT). HT is the most common thyroid inflammation characterized by abnormally elevated thyroglobulin antibodies (TGAb) and

Open access

A Rouland, J-C Chauvet-Gelinier, A-L Sberna, E Crevisy, P Buffier, T Mouillot, J-M Petit and B Vergès

assessment and compare the Type A profiles of patients with T1D and patients presenting with other auto-immune disease (Gravesdisease or Hashimoto’s thyroiditis), in order to validate the hypothesis that increased Type A personality traits is related to the